GlassScriptPhysician profile
Adolphus Anekwe
NPI 1750303343
$6,180.33
in general payments reported to CMS, 2019-2025
35 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $679 · 2021: $732 · 2022: $1,099 · 2023: $678 · 2024: $1,126 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,159.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $740.50 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Merck Sharp & Dohme LLC | $551.61 | 2020-2024 | Verquvo |
| Novo Nordisk INC | $493.71 | 2019-2024 | |
| Lundbeck LLC | $351.37 | 2023-2025 | Rexulti |
| Dexcom, INC. | $333.52 | 2021-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $307.40 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $280.75 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $280.56 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $263.66 | 2020-2021 | |
| Allergan, INC. | $241.56 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $160.71 | 2023-2025 | Rexulti |
| Abbott Laboratories | $112.70 | 2021-2025 | Freestyle Libre 3 |
| Global Blood Therapeutics, INC. | $78.21 | 2022 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolphus Anekwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.